Insmed (INSM) Competitors $96.30 -1.94 (-1.97%) As of 10:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INSM vs. GSK, REGN, ALNY, ARGX, BNTX, RPRX, BIIB, ILMN, GMAB, and INCYShould you be buying Insmed stock or one of its competitors? The main competitors of Insmed include GSK (GSK), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), argenex (ARGX), BioNTech (BNTX), Royalty Pharma (RPRX), Biogen (BIIB), Illumina (ILMN), Genmab A/S (GMAB), and Incyte (INCY). These companies are all part of the "med - biomed/gene" industry. Insmed vs. Its Competitors GSK Regeneron Pharmaceuticals Alnylam Pharmaceuticals argenex BioNTech Royalty Pharma Biogen Illumina Genmab A/S Incyte Insmed (NASDAQ:INSM) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment. Do analysts prefer INSM or GSK? Insmed presently has a consensus price target of $106.80, indicating a potential upside of 10.90%. GSK has a consensus price target of $37.38, indicating a potential downside of 2.06%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than GSK.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Insmed 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00GSK 1 Sell rating(s) 8 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.10 Which has stronger earnings & valuation, INSM or GSK? GSK has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInsmed$363.71M50.23-$913.77M-$5.95-16.18GSK$40.10B1.95$3.29B$1.9419.67 Does the media refer more to INSM or GSK? In the previous week, GSK had 14 more articles in the media than Insmed. MarketBeat recorded 18 mentions for GSK and 4 mentions for Insmed. Insmed's average media sentiment score of 0.99 beat GSK's score of 0.37 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GSK 8 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, INSM or GSK? Insmed has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Do insiders and institutionals have more ownership in INSM or GSK? 15.7% of GSK shares are owned by institutional investors. 3.0% of Insmed shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is INSM or GSK more profitable? GSK has a net margin of 9.89% compared to Insmed's net margin of -265.93%. GSK's return on equity of 48.82% beat Insmed's return on equity.Company Net Margins Return on Equity Return on Assets Insmed-265.93% -446.98% -52.70% GSK 9.89%48.82%11.15% SummaryGSK beats Insmed on 11 of the 17 factors compared between the two stocks. Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INSM vs. The Competition Export to ExcelMetricInsmedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.27B$2.90B$5.50B$9.00BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-16.1821.2326.5720.02Price / Sales50.23280.33415.46120.95Price / CashN/A41.4736.1356.90Price / Book60.197.498.065.50Net Income-$913.77M-$55.05M$3.15B$248.50M7 Day Performance-5.35%2.58%1.72%2.61%1 Month Performance31.77%5.22%3.92%5.42%1 Year Performance55.32%5.04%35.02%20.76% Insmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INSMInsmed4.0347 of 5 stars$96.30-2.0%$106.80+10.9%+52.3%$18.27B$363.71M-16.181,271GSKGSK2.0685 of 5 stars$38.26+0.5%$37.38-2.3%+0.8%$78.33B$40.10B19.7268,629Options VolumeREGNRegeneron Pharmaceuticals4.9404 of 5 stars$511.44+0.3%$836.48+63.6%-47.6%$55.22B$14.20B13.0215,106Trending NewsAnalyst DowngradeALNYAlnylam Pharmaceuticals4.3008 of 5 stars$313.19+1.1%$319.58+2.0%+33.2%$40.84B$2.25B-149.852,230Positive NewsAnalyst ForecastARGXargenex4.3177 of 5 stars$541.60-0.1%$709.18+30.9%+25.2%$33.07B$2.25B33.411,599Analyst ForecastBNTXBioNTech2.5077 of 5 stars$103.11-3.2%$137.86+33.7%+37.5%$24.79B$2.98B-30.336,772RPRXRoyalty Pharma4.9162 of 5 stars$35.43+1.6%$47.33+33.6%+39.8%$19.92B$2.26B19.1580Positive NewsBIIBBiogen4.9581 of 5 stars$124.66-1.9%$188.19+51.0%-41.8%$18.27B$9.68B12.317,605ILMNIllumina4.8779 of 5 stars$90.61+0.1%$126.94+40.1%-4.9%$14.34B$4.34B-14.939,030Positive NewsGMABGenmab A/S3.8935 of 5 stars$20.66-2.4%$39.17+89.6%-17.9%$13.24B$3.12B11.742,682High Trading VolumeINCYIncyte4.3769 of 5 stars$67.28-1.7%$74.53+10.8%+15.5%$13.02B$4.41B210.242,617 Related Companies and Tools Related Companies GSK Competitors Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors argenex Competitors BioNTech Competitors Royalty Pharma Competitors Biogen Competitors Illumina Competitors Genmab A/S Competitors Incyte Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INSM) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.......Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
